LK-2 Small Molecule Compound for Ischemic Stroke Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule pharmaceuticals, such as Selfotel, that target ASIC1a and NMDARs for treating ischemic stroke, either fail to significantly reduce mortality or cause psychiatric side effects due to their strong blocking effects on NMDARs, which are crucial for normal brain function.
Innovation Solution
A novel small molecule compound, 4-(phenyl (phosphinoyl) methyl) piperazine-2-carboxylic acid (LK-2), is developed, which can completely block the activation of ASICs by glutamate while partially blocking the activation of NMDARs, thereby minimizing the impact on physiological NMDAR functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Selfotel is used as a competitive antagonist of NMDARs to block glutamate binding, then the blocking effect on NMDARs is enhanced, but the physiological function and neuroprotective effects of NMDARs are also blocked, leading to psychiatric side effects and trial failure
Solution Approach 1:
The patent applies local quality by designing a compound that selectively targets specific receptor subtypes or locations. LK-2 is engineered to have differentiated binding properties where it can block pathological NMDAR activation in ischemic tissue while preserving physiological NMDAR functions in healthy brain regions, achieving spatially selective pharmacological action
Solution Approach 2:
The patent changes the pharmacological parameters by modifying the chemical structure from Selfotel to LK-2, which alters the binding affinity and selectivity profile. This structural modification results in different IC50 values and binding characteristics that allow partial blocking of NMDARs while maintaining physiological functions, resolving the contradiction between blocking efficacy and side effects
2Reliability
If a small molecule compound completely blocks ASICs activation by glutamate, then neuroprotection against stroke-induced brain injury is improved, but the risk of affecting normal brain function increases
Solution Approach 1:
The patent applies partial action by designing LK-2 to achieve complete blocking of ASICs activation (excessive action on target) while using selective pharmacological properties to limit the impact on normal brain function. The compound is optimized to have high affinity for ASICs specifically activated during ischemia, allowing complete blockade of pathological processes while minimizing effects on physiological ASIC functions
Data Source
AI summary
The present invention provides a small molecule compound for treating ischemic stroke, which is 4-(phenyl (phosphinoyl) methyl) piperazine-2-carboxylic acid. This small molecule compound can completely block the activation of ASICs by glutamate, and partially block the activation of NMDARs by glutamate, achieving the purpose of not affecting the physiological function of NMDARs, thereby reducing the side effects of mental symptoms and even mortality in stroke patients, and providing an effective strategy for treating ischemic stroke. In addition, the synthesis method of this small molecule compound is simple, which can reduce the cost of the pharmaceutical and has good application prospects.